Medikaloka Hermina PT (HEAL) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Medikaloka Hermina PT IDR 599, price IDR 640, upside -6.4%, quality 40 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Medikaloka Hermina PT for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range 640.00 IDR – 1,739 IDR · fair‑value band 419.29 IDR – 771.10 IDR · the 640.00 IDR price screens above the 598.99 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Medikaloka Hermina PT in your weekly email
Every Wednesday you see whether Medikaloka Hermina PT is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PT Medikaloka Hermina Tbk, together with its subsidiaries, operates a network of hospitals in Indonesia.
Show more
PT Medikaloka Hermina Tbk, together with its subsidiaries, operates a network of hospitals in Indonesia. The company offers services in the areas of medical acupuncture, pediatrics, surgery, plastic and reconstructive surgery, neurosurgery, emergency medicine, forensic and medicolegal, dentistry, clinical nutrition, integrative medicine, cardiology, obstetrics and gynecology, primary care family medicine, nuclear medicine and molecular theranostics, psychiatry, andrology, dietetics, lactation counseling, and dermatology and venereology. It also provides services in the areas of ophthalmology, clinical microbiology, pediatric neurology, occupational, radiation oncology, orthopedics and traumatology, pulmonology, anatomical pathology, clinical pathology, anesthesiology, internal medicine, psychology, radiology, physical medicine and rehabilitation, neurology, sports medicine specialist, aviation specialist, radiation specialist, otorhinolaryngology, occupational therapy, and urology. In addition, the company offers digital subtraction angiography, gastroenterology, IVF clinic, sleep and snoring clinic, pain clinic, growth and development clinic, stem cell, palliative care, perinatology ward, integrated stroke, and medical tourism services. Further, it is involved in investment, service, trading, management consulting, nurse training, and education services. PT Medikaloka Hermina Tbk was founded in 1985 and is headquartered in Jakarta Timur, Indonesia.
Stock analysis
Medikaloka Hermina PT (HEAL) currently trades at 640.00 IDR, while our model-based Fair Value estimate is 598.99 IDR, implying the stock looks roughly 6.8% fairly valued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 616.88 IDR per share, and 4 of the 14 models we run sit above the 640.00 IDR price.
Bear case: the Asset-Based group reads lowest at 248.27 IDR, and 10 of the 14 models stay below the price. Evidence for this calculation is low.
Scenario range: 419.29 IDR (bear) to 771.10 IDR (bull), the price of 640.00 IDR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Medikaloka Hermina PT reported revenue of 7.1T IDR in FY2025 versus 5.8T IDR in FY2021, a compound +5.2%/yr. Reported net income was 430B IDR in FY2025, compounding −19.0%/yr from FY2021.
Key figures
Market cap 13.9T IDR (≈ $1.4B) · P/E ratio 24.1 · P/S ratio 1.45 · EPS (TTM) 26.61 IDR · Net margin 6.0% · Return on equity 7.8% · Return on assets (EBIT) 11.6% · Operating margin 12.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).
What moves the price
The share trades about 62% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at −6%, HEAL screens richer than that median.
Fair Value models
Bear 419.29 IDRFair Value 598.99 IDRBull 771.10 IDR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (19.47 IDR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.43/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+5.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.1%
Start year 2020 (pandemic). Over 10 years: +15.4% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.4%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in IDR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−8.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−8.1%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−8% vs 26%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.24% → 13%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 258 stocks
Beats the industry median on 5/14 measures
Overall it trails its industry peers.
Valuation
Quality Score40 · Bottom 25%
Fair Value upside−6% · Below median
Profitability
Return on equity (TTM)8% · Above median
Return on assets5% · Above median
Net margin (TTM)6% · Above median
Operating margin (TTM)13% · Above median
Growth and dividend
Revenue growth5% · Below median
Dividend yield (TTM)0.0% · Bottom 25%
Balance sheet
Debt / equity0.47× · Above median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Medikaloka Hermina PT (HEAL) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of 598.99 IDR versus a price of 640.00 IDR, about −6% upside (fairly valued).
What is the fair value of HEAL?
Our model-based fair value for Medikaloka Hermina PT is 598.99 IDR (as of Sep 23, 2026), built from audited fundamentals. The current price: 640.00 IDR.
What is the quality score of HEAL?
Medikaloka Hermina PT has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medikaloka Hermina PT (HEAL)?
Our model-based price target is the fair value of 598.99 IDR (as of Sep 23, 2026) from 14 valuation models. Cautious scenario 419.29 IDR, optimistic scenario 771.10 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Medikaloka Hermina PT stock forecast for 2026?
Our models put fair value at 598.99 IDR, about −6% upside versus a price of 640.00 IDR (fairly valued). Cautious scenario 419.29 IDR, optimistic scenario 771.10 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Medikaloka Hermina PT (HEAL)?
Medikaloka Hermina PT reported trailing-twelve-month revenue of about 7.2T IDR (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Medikaloka Hermina PT (HEAL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medikaloka Hermina PT it is 598.99 IDR per share (as of Sep 23, 2026), against a price of 640.00 IDR. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Medikaloka Hermina PT stock overvalued or undervalued in 2026?
As of Sep 23, 2026, HEAL trades above its calculated fair value: price 640.00 IDR, fair value 598.99 IDR, a gap of about −6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HEAL?
No. The price is what the market pays today (640.00 IDR); the fair value is what the company's own numbers justify (598.99 IDR). For Medikaloka Hermina PT the two are 41.01 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Medikaloka Hermina PT worth?
The market values Medikaloka Hermina PT at about 13.9T IDR (market capitalisation, as of Sep 23, 2026). Per share that is 640.00 IDR; our models calculate a fair value of 598.99 IDR per share.
What do the bullish and bearish scenarios say about HEAL?
Our models span a range for Medikaloka Hermina PT: cautious scenario 419.29 IDR, base 598.99 IDR, optimistic 771.10 IDR per share (as of Sep 23, 2026, price 640.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of HEAL?
Medikaloka Hermina PT trades at a price-to-earnings ratio of 24.1 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 598.99 IDR is built from several models across several years. Other multiples: PEG 5.7, P/B 2.4, P/S 1.9, EV/EBITDA 8.2.
What is the PEG ratio of HEAL?
The PEG ratio of Medikaloka Hermina PT is 5.73 (P/E divided by earnings growth, as of Sep 23, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Medikaloka Hermina PT (HEAL)?
Balance-sheet figures for Medikaloka Hermina PT (as of Sep 23, 2026): return on equity 7.8%, debt of 0.47 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is HEAL from its 52-week high?
Medikaloka Hermina PT trades at 640.00 IDR, about 62% below its 52-week high of 1,665 IDR and at the low of 640.00 IDR (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 598.99 IDR is for.
Which stocks are comparable to Medikaloka Hermina PT?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medikaloka Hermina PT stock attractive at the current price?
The data as of Sep 23, 2026: price 640.00 IDR, calculated fair value 598.99 IDR (−6%), Quality Score 40/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HEAL calculated?
We run Medikaloka Hermina PT through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 598.99 IDR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Medikaloka Hermina PT itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medikaloka Hermina PT (HEAL)?
The closing price on Sep 23, 2026 was 640.00 IDR. Our model-based fair value is 598.99 IDR, about −6% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medikaloka Hermina PT right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (419.29 IDR to 771.10 IDR) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Medikaloka Hermina PT
How large is the market capitalisation of Medikaloka Hermina PT (HEAL)?
The market capitalisation of Medikaloka Hermina PT is 13.9T IDR (≈ $1.4B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medikaloka Hermina PT (HEAL)?
The price-to-sales ratio of Medikaloka Hermina PT is 1.45 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medikaloka Hermina PT (HEAL)?
Earnings per share at Medikaloka Hermina PT are 26.61 IDR (price ÷ EPS = P/E 24.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Medikaloka Hermina PT (HEAL)?
The net margin of Medikaloka Hermina PT is 6.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medikaloka Hermina PT (HEAL)?
The return on equity (ROE) of Medikaloka Hermina PT is 7.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medikaloka Hermina PT (HEAL)?
On an EBIT basis the return on assets of Medikaloka Hermina PT is 11.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medikaloka Hermina PT (HEAL)?
The operating margin of Medikaloka Hermina PT is 12.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medikaloka Hermina PT (HEAL)?
Revenue at Medikaloka Hermina PT is growing +5.4% versus a year earlier (3y avg +13.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Medikaloka Hermina PT (HEAL)?
Earnings per share at Medikaloka Hermina PT are growing −18.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Medikaloka Hermina PT (HEAL) generate?
The free cash flow of Medikaloka Hermina PT is −612B IDR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Medikaloka Hermina PT (HEAL) carry?
The net debt of Medikaloka Hermina PT is 2.5T IDR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Medikaloka Hermina PT in the live analysis
One click puts Medikaloka Hermina PT on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
